Q-Line Biotech Limited

## 6. Segment Disclosure

During the period of Restatement, Company is engaged into Manufacturing and Trading to Biochemistry Regnant, Instruments and Consumables. Disclosure as per AS -17 is given below-

(Rs in Lakhs)

<table><thead><tr><th colspan="4">RESTATED CONSOLIDATED STATEMENT OF SEGMENT REPORTING</th></tr><tr><th rowspan="2">Sr. No.</th><th rowspan="2">Particulars</th><th colspan="3">(Amount in Rs. Lakhs)</th></tr><tr><th>As at March 31, 2025</th><th>As at March 31, 2024</th><th>As at March 31, 2023</th></tr></thead><tbody><tr><td></td><td><strong>Segment-wise Revenue</strong></td><td></td><td></td><td></td></tr><tr><td></td><td>Manufacturing</td><td>16,897.01</td><td>7,005.41</td><td>5,087.22</td></tr><tr><td></td><td>Trading</td><td>14,481.03</td><td>13,359.20</td><td>13,186.42</td></tr><tr><td></td><td><strong>Total</strong></td><td><strong>31,378.04</strong></td><td><strong>20,364.61</strong></td><td><strong>18,273.63</strong></td></tr><tr><td></td><td>Less: Inter-segment revenue (if any)</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td><strong>Net Sales or Income from Operation</strong></td><td><strong>31,378.04</strong></td><td><strong>20,364.61</strong></td><td><strong>18,273.63</strong></td></tr><tr><td></td><td><strong>Segment-wise Results</strong></td><td></td><td></td><td></td></tr><tr><td></td><td>Profit/Loss before interest and Tax</td><td></td><td></td><td></td></tr><tr><td></td><td>Manufacturing</td><td>8,023.62</td><td>3,540.50</td><td>3,132.78</td></tr><tr><td></td><td>Trading</td><td>5,490.08</td><td>5,164.68</td><td>5,123.46</td></tr><tr><td></td><td><strong>Total</strong></td><td><strong>13,513.70</strong></td><td><strong>8,705.18</strong></td><td><strong>8,256.24</strong></td></tr><tr><td></td><td>Less: Interest</td><td>1,470.00</td><td>627.52</td><td>379.60</td></tr><tr><td></td><td>Less: Other Unallocable Expenses net of other Un-allocable Income</td><td>5,927.94</td><td>5,017.50</td><td>4,892.65</td></tr><tr><td></td><td><strong>Total Profit Before Tax</strong></td><td><strong>6,115.76</strong></td><td><strong>3,060.16</strong></td><td><strong>2,983.99</strong></td></tr><tr><td></td><td><strong>Segment-wise Assets</strong></td><td></td><td></td><td></td></tr><tr><td></td><td>Manufacturing</td><td>17,589.38</td><td>9,313.79</td><td>3,414.33</td></tr><tr><td></td><td>Trading</td><td>8,063.19</td><td>7,436.99</td><td>5,701.81</td></tr><tr><td></td><td>Other Unallocable Assets</td><td>19,896.02</td><td>17,173.82</td><td>16,041.82</td></tr><tr><td></td><td><strong>Total</strong></td><td><strong>45,548.59</strong></td><td><strong>33,924.60</strong></td><td><strong>25,157.96</strong></td></tr><tr><td></td><td><strong>Segment-wise Liabilities</strong></td><td></td><td></td><td></td></tr><tr><td></td><td>Manufacturing</td><td>2,854.23</td><td>1,914.41</td><td>526.61</td></tr><tr><td></td><td>Trading</td><td>2,708.26</td><td>4,009.35</td><td>3,444.01</td></tr><tr><td></td><td>Other Unallocable Liabilities</td><td>39,986.10</td><td>28,000.84</td><td>21,187.34</td></tr><tr><td></td><td><strong>Total</strong></td><td><strong>45,548.59</strong></td><td><strong>33,924.60</strong></td><td><strong>25,157.96</strong></td></tr></tbody></table>

## 7. Auditors Qualifications â€“

Details of Auditors qualifications and their impact on restated financial statement is given below.

a) Qualification which required adjustment in restated financial statements

<table><thead><tr><td>Financial Year</td><td>Audit Qualifications</td><td>Remark</td></tr></thead><tbody><tr><td>FY 2022-23</td><td>NIL</td><td></td></tr><tr><td>FY 2023-24</td><td>NIL</td><td></td></tr></tbody></table>

194